Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Elicio Therapeutics (ELTX) Gross Margin (2020 - 2021)

Elicio Therapeutics filings provide 2 years of Gross Margin readings, the most recent being 98.28% for Q4 2021.

  • On a quarterly basis, Gross Margin fell 738.0% to 98.28% in Q4 2021 year-over-year; TTM through Dec 2021 was 98.43%, a 17866.0% decrease, with the full-year FY2022 number at 100.0%, up 157.0% from a year prior.
  • Gross Margin hit 98.28% in Q4 2021 for Elicio Therapeutics, down from 100.0% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 105.66% in Q4 2020 to a low of 54.32% in Q2 2020.